Gold prices fell slightly to around $4,122.50 an ounce amid ongoing inflation concerns and expectations of further Federal Reserve rate hikes, despite weaker U.S. housing data and a drop in crude oil prices. Housing starts and pending home sales declined sharply, signaling economic slowdown, but inflation remains elevated with consumer and producer prices rising. The market expects the Fed to pause rate hikes in October but continue tightening in December. Oil prices initially surged on Middle East tensions but retreated on talks of U.S.-Iran negotiations, easing some inflation pressure. Investors remain cautious, focusing on upcoming economic reports and Fed decisions that will influence interest rates and market direction.
Gold prices are under pressure despite falling yields and Middle East diplomacy affecting oil prices. For readers following US stocks, here is Pluang's market snapshot as of Oct 21, 2026 03:02 WIB: out of 150 stocks, 87 rose and 62 fell. Notable movers include ZM at USD 94.00 with a 1-day change of -4.58% and 100% sell order activity, NU at USD 15.16 with a 1-day change of +4.48% and balanced buy/sell orders, and KEY at USD 20.81 with a 1-day change of +4.47%.
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
Heartland Express reported a third-quarter 2026 revenue decline of 8.7% to $179.5 million, missing analyst estimates. Despite lower revenue, the company returned to profitability with a net income of $1.0 million, compared to a loss last year. The op...
